Status:
RECRUITING
Unveiling the Germline Predisposition to Myeloproliferative Neoplasms
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
Myeloproliferative Disease
Germline Mutation
Eligibility:
All Genders
18+ years
Brief Summary
The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of ...
Eligibility Criteria
Inclusion
- A diagnosis of PV, ET, prePMF, overt PMF or MPN-U according to 2016 WHO criteria
- Characterization of the MPN driver mutation performed at any moment before enrolment
- diagnosis of MPN made when the patient was younger than 27 years old OR at least a second case of hematologic malignancies in first or second-degree relatives
Exclusion
- None
Key Trial Info
Start Date :
June 27 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
313 Patients enrolled
Trial Details
Trial ID
NCT07204392
Start Date
June 27 2022
End Date
December 31 2030
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy, 27100